HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy.

AbstractBACKGROUND:
Hypertrophic cardiomyopathy is a primary cardiac disease characterized by left ventricular hypertrophy, myocyte hypertrophy and irregularities and interstitial fibrosis in the absence of any cardiac or systemic diseases and may lead to sudden cardiac death (SCD). Galectin-3 is a β-galactoside-binding lectin that has been associated with cardiac fibrosis and inflammation. In this study, we aimed to investigate the relationship between serum galectin-3 levels and the criteria for 5-year sudden death risk, recently defined in the European Society of Cardiology guidelines (2014), in patients with hypertrophic cardiomyopathy.
MATERIALS AND METHODS:
A total of 52 hypertrophic cardiomyopathy patients were enrolled in the study. Patients were questioned for sudden death risk predictors as outlined in the 2014 European Society of Cardiology guideline. A standardized clinical evaluation was carried out on the basis of previously described prognostic variables to calculate the 5-year risk of SCD. Blood samples were taken from all patients to measure serum galectin-3 levels. A statistical significance level of P < 0.05 was accepted in all tests.
RESULTS:
We found that there was a significant correlation between the estimated 5-year risk of SCD and serum levels of galectin-3.
CONCLUSIONS:
Galectin-3 may be an inexpensive and easily accessible parameter to predict arrhythmia risk. In addition, it can be used to determine antiarrhythmic prophylaxis as a predictor of an arrhythmia storm in implantable cardioverter defibrillator-implanted patients who are not available for magnetic resonance imaging.
AuthorsSamim Emet, Mubariz Dadashov, Mehmet Rasih Sonsoz, Mustafa Ozan Cakir, Mustafa Yilmaz, Ali Elitok, Ahmet Kaya Bilge, Fehmi Mercanoglu, Aytac Oncul, Kamil Adalet, Imran Onur
JournalThe American journal of the medical sciences (Am J Med Sci) Vol. 356 Issue 6 Pg. 537-543 (12 2018) ISSN: 1538-2990 [Electronic] United States
PMID30342718 (Publication Type: Journal Article)
CopyrightCopyright © 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Blood Proteins
  • Galectin 3
  • Galectins
  • LGALS3 protein, human
Topics
  • Adult
  • Aged
  • Biomarkers (blood)
  • Blood Proteins
  • Cardiomyopathy, Hypertrophic (complications)
  • Death, Sudden, Cardiac (epidemiology)
  • Female
  • Galectin 3 (blood)
  • Galectins
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Turkey (epidemiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: